Thu, Jul 24, 2014, 2:15 PM EDT - U.S. Markets close in 1 hr 45 mins

Recent

% | $
Click the to save as a favorite.

Silver Wheaton Corp. Message Board

silverisgold88 5 posts  |  Last Activity: 1 hour 59 minutes ago Member since: Feb 9, 2009
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    What a climate shift...

    by wilderguide May 1, 2014 9:36 PM
    silverisgold88 silverisgold88 May 2, 2014 7:37 AM Flag

    oncodoc, wilder - please do not let the naysayers and idiots here keep you from posting. There are several longs here like myself who appreciate your input and knowledge. I do not post that often but I do read intelligent posts that the two of you and some others offer. We will keep giving you thumbs up! Keep up the good work!

  • silverisgold88 by silverisgold88 May 29, 2014 6:34 PM Flag

    I figured there would be more shares traded today in anticipation of possible positive news.

  • I thought 7001ctc`s comment was worth sharing here - "I'm a 16 year survivor of castrate resistant prostrate cancer, successfully treated to date by the founder of the Prostate Cancer Research Institute, Dr. Mark Scholz. I am also the president of the network serving over 100 worldwide patients of this worst kind of PC.

    Several years ago, during the annual PCRI annual conference, attended by over 500 oncologists and patients, Dr. Scholz showed the incredible results of a ,metastatic patient with tumors throughout his body treated with Carbo(sic) for 6 months. Every one of the multiple tumors, except one tiny one, had disappeared. Dr, Scholz said "in all my experience of treating many hundreds of metastatic patients, I've never seen such a positive result".

    That is why I'm a believer in the future of Cabo."

  • • In an interview with TheStreet's Adam Feuerstein, David Miller elaborates on his view that Roche (RHHBY +1.3%) has a strong incentive to acquire Exelixis (EXEL +10.7%) in order to capture the full margin of the combination therapy cobimetinib and currently-approved Zelboraf (vemurafenib). He says that the combo regimen could reach peak sales of $1B and should be priced at a premium to Glaxo's (GSK -0.4%) inferior offering of Tafinlar and Mekinist. He believes it will establish itself as the standard of care as a first-line therapy for BRAF-mutated melanoma.
    • Earlier today, Roche announced positive results from a Phase 3 clinical trial where patients lived significantly longer when treated with the combo regimen compared to placebo.

  • Reply to

    I like EXEL -- any new news released?

    by smithts777 2 hours 8 minutes ago
    silverisgold88 silverisgold88 1 hour 59 minutes ago Flag

    Look at PBYI - Puma Biotechnology. Went from $60 to $233 yesterday on cancer drug success.

SLW
26.02-0.41(-1.55%)2:15 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.